Project information
From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
- Project Identification
- MSM0021622434
- Project Period
- 1/2007 - 12/2013
- Investor / Pogramme / Project type
-
Ministry of Education, Youth and Sports of the CR
- Research Intents
- MU Faculty or unit
- Faculty of Medicine
- Keywords
- multiple myeloma; proteomics; genomics
Monoclonal gammapathies and multiple myeloma in particular are among the most common and debilitating malignancies in the elderly population. In the last decade, there have been dramatic developments in basic and applied research in the field. New treatments have become available and treatment standards have changed. Treatment results have substantially improved and the probability of 10-year survival increased from 5% to 20% in the last decade. However, the disease is still incurable. The treatment strategy today includes potentially 3-5 regimens administered over a period of 10 to 15 years. There is increased tendency to apply treatment specifically tailored for a subgroup of patients with a well-defined risk and response rate.
Publications
Total number of publications: 314
2010
-
Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting
International journal of hematology, year: 2010, volume: 92, edition: 2
-
Pacientka s AL- amyloidózou a závažným deficitem faktoru X je po vysokodávkované chemoterapii již 7 let v kompletní hematologické remisi s normální aktivitou faktoru X. Popis případu a přehled literatury
Vnitřní lékařství, year: 2010, volume: 56, edition: 1
-
Phenotypic Analysis of CD19+ Subsets In Monoclonal Gammopathy Patients
Year: 2010, type: Conference abstract
-
Plasma cell phenotype in MGUS and MM cases
Year: 2010, type: Conference abstract
-
Poškození ledvin při mnohočetném myelomu a dalších monoklonálních gamapatiích
Akutní poškození a selhání ledvin, edition: Vyd. 1, year: 2010, number of pages: 32 s.
-
Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma.
Neoplasma, year: 2010, volume: 57, edition: 1
-
Prognostic and predictive impact of cytogenetic changes in relapsed multiple myeloma patients treated with bortezomib or thalidomid based regiments: a Czech group experience
Year: 2010, type: Conference abstract
-
Proteomic investigation of multiple myeloma by LC-MS/MS and 2-DE experimental strategies: a comparative study
Year: 2010, type: Conference abstract
-
Proteomická analýza proteinů krevní plazmy u mnohočetného myelomu s využitím dvourozměrné elektroforézy v polyakrylamidovém gelu a hmotnostní spektrometrie
Year: 2010, type: Conference abstract
-
Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.
British journal of haematology, year: 2010, volume: 149, edition: 3